4 December 2023 in Nature Cell Biology
Lineage transitions are a central feature of prostate development, tumourigenesis and treatment resistance. While epigenetic changes are well known to drive prostate lineage transitions, it remains unclear how upstream metabolic signalling contributes to the regulation of prostate epithelial identity. To fill this gap, we developed an approach to perform metabolomics on primary prostate epithelial cells. Using this approach, we discovered that the basal and luminal cells of the prostate exhibit distinct metabolomes and nutrient utilization patterns. Furthermore, basal-to-luminal differentiation is accompanied by increased pyruvate oxidation. We establish the mitochondrial pyruvate carrier and subsequent lactate accumulation as regulators of prostate luminal identity. Inhibition of the mitochondrial pyruvate carrier or supplementation with exogenous lactate results in large-scale chromatin remodelling, influencing both lineage-specific transcription factors and response to antiandrogen treatment. These results establish reciprocal regulation of metabolism and prostate epithelial lineage identity.
1 September 1994 in Abdominal Radiology
1 December 2016 in Journal of Clinical and Translational Endocrinology: Case Reports
A 52-year old male with a history of insulin treated T2DM complicated by end stage renal disease (ESRD requiring hemodialysis and prior gastric bypass surgery presented with severe recurrent hypoglycemia with seizures. A 72 hour fast demonstrated hyperinsulinemic hypoglycemia. Abdominal CT scan and endoscopic ultrasound guided biopsy demonstrated a pancreatic neuroendocrine tumor (pNET). Symptoms persisted despite pNET resection and on further testing he was found to have a highly specific insulin antibody resulting in insulin autoimmune syndrome. He responded well to prednisone therapy with resolution of hypoglycemia and decline in the insulin autoantibody titers. This study concludes that autoimmune forms of hypoglycemia are uncommon and interpretation of tests can be challenging. However, insulin autoimmune syndrome (IAS) should be considered in a patient with both fasting and postprandial hypoglycemia in setting of very high insulin levels with associated anti-insulin antibodies and elevated insulin to C peptide molar ratio
7 November 2023 in Science Signaling
Dysregulated Notch signaling is a common feature of cancer; however, its effects on tumor initiation and progression are highly variable, with Notch having either oncogenic or tumor-suppressive functions in various cancers. To better understand the mechanisms that regulate Notch function in cancer, we studied Notch signaling in a Drosophila tumor model, prostate cancer–derived cell lines, and tissue samples from patients with advanced prostate cancer. We demonstrated that increased activity of the Src-JNK pathway in tumors inactivated Notch signaling because of JNK pathway–mediated inhibition of the expression of the gene encoding the Notch S2 cleavage protease, Kuzbanian, which is critical for Notch activity. Consequently, inactive Notch accumulated in cells, where it was unable to transcribe genes encoding its target proteins, many of which have tumor-suppressive activities. These findings suggest that Src-JNK activity in tumors predicts Notch activity status and that suppressing Src-JNK signaling could restore Notch function in tumors, offering opportunities for diagnosis and targeted therapies for a subset of patients with advanced prostate cancer.
27 January 2026 in Molecular Cancer Research
As cancer cells evade therapeutic pressure and adopt alternate lineage identities not commonly observed in the tissue of origin, they likely adopt alternative metabolic programs to support their evolving demands. Targeting these alternative metabolic programs in distinct molecular subtypes of aggressive prostate cancer may lead to new therapeutic approaches to combat treatment resistance. We identify the poorly studied metabolic enzyme oxoglutarate dehydrogenase-like (OGDHL), named for its structural similarity to the tricarboxylic acid (TCA) cycle enzyme oxoglutarate dehydrogenase, as an unexpected regulator of tumor growth, treatment-induced lineage plasticity, and DNA damage in prostate cancer. Although OGDHL has been described as a tumor suppressor in various cancers, we find that its loss impairs prostate cancer cell proliferation and tumor formation. Loss of OGDHL reduces nucleotide synthesis, induces accumulation of the DNA damage response marker γH2AX, and alters androgen receptor inhibition–induced plasticity. Our data suggest that OGDHL has minimal impact on TCA cycle activity and that mitochondrial localization is not required for its regulation of nucleotide metabolism. Finally, we demonstrate that OGDHL expression is tightly correlated with neuroendocrine (NE) differentiation in clinical prostate cancer and that knockdown of OGDHL impairs the growth of cell line models of NE prostate cancer. These findings underscore the importance of investigating poorly characterized metabolic genes as potential regulators of distinct molecular subtypes of aggressive cancer. Implications: OGDHL emerged as an unexpected metabolic dependency associated with lineage plasticity and NE differentiation, implicating poorly studied metabolic enzymes as potential targets for treatment-resistant prostate cancer.